{
    "clinical_study": {
        "@rank": "57116", 
        "arm_group": {
            "arm_group_label": "Cancer patients", 
            "description": "Patient with histologically confirmed diagnosis of cervical cancer or cervical intraepithelial neoplasia (grade 3) or of high-grade serous (or undifferentiated) ovarian cancer or patients with AML or CML confirmed by bone marrow biopsy or peripheral blood Not treated - prior standard of care therapy acceptable one blood sampling performed on the visit day"
        }, 
        "biospec_descr": {
            "textblock": "PBMCs isolated from whole blood"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This study is a clinical study aiming at establishing immunological assays for the\n      qualitative and quantitative evaluation of WT-1, Survivin and HPV16 E7-specific immune\n      responses in cancer patients. Such a study will allow the development of suitable\n      immunological tools to be used in assessing response in a subsequent phase I study aiming at\n      evaluating therapeutic vaccine candidates targeting WT-1, Survivin and/or HPV16\n      E7-expressing tumors. In addition, this study will help defining the baseline\n      cancer-associated immune responses in the selected patient population.\n\n      Cervical and ovarian cancer patients, as well as leukemia patients, will be included in this\n      study.\n\n      WT-1, Survivin and HPV-specific immune responses will be monitored in these patients by ex\n      vivo and cultured IFNg ELISpot as well as tetramer staining."
        }, 
        "brief_title": "Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ovarian Serous Adenocarcinoma", 
            "Undifferentiated Carcinoma of Ovary", 
            "Cervical Cancer", 
            "Cervical Intraepithelial Neoplasia, Grade 3", 
            "Acute Myeloid Leukemia", 
            "Chronic Myeloid Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Neoplasms", 
                "Carcinoma", 
                "Uterine Cervical Neoplasms", 
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
                "Ovarian Neoplasms", 
                "Neoplasms, Glandular and Epithelial", 
                "Cystadenocarcinoma, Serous", 
                "Cervical Intraepithelial Neoplasia", 
                "Carcinoma in Situ"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Specific Inclusion criteria\n\n          -  For ovarian cancer patients: Histologically confirmed surgical diagnosis of\n             high-grade serous (or undifferentiated) ovarian cancer\n\n          -  For CIN3 and cervical cancer patients: Histologically confirmed diagnosis of CIN3 or\n             cervical cancer\n\n          -  For AML and CML patients: HLA-A2 positivity and diagnosis of AML or CML confirmed by\n             bone marrow biopsy or peripheral blood\n\n          -  Shared inclusion criteria\n\n          -  No evidence of active progressive disease. For ovarian cancer patients, a woman with\n             a rising CA125 and negative imaging is acceptable\n\n          -  Age \u2265 18 yrs and < 70 yrs\n\n          -  ECOG 0-2\n\n          -  Adequate hematologic assessment (results from the previous standard of care visit):\n\n          -  Absolute neutrophil count (ANC) greater than or equal to 1.0 x 109/L\n\n          -  Platelets greater than or equal to 100 x 109/L.\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Treatment with chemotherapy, radiation therapy, other immunotherapy or non-topical\n             steroids within the past 3 weeks prior to initiation of the study.\n\n          -  Immunosuppressive therapy (excluding topical steroids) for any other condition.\n\n          -  Recurrent/progressive disease confirmed clinically, radiologically or histologically\n             before entry into the study. (exclude versus inclusion criteria)\n\n          -  Persistent fever (>24 hours) documented by repeated measurement or active\n             uncontrolled infection in the last 4 weeks.\n\n          -  Active autoimmune disease, including, but not limited to, SLE, MS, ankylosing\n             spondylitis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Three type of patients will be enrolled in this study:\n\n          -  Women with a confirmed diagnosis of serous or undifferentiated ovarian cancer\n\n          -  Women with a confirmed diagnosis of CIN3 or cervical cancer\n\n          -  HLA-A2 positive men or women with a confirmed diagnosis of AML of CML All these\n             patients will be less than 70 years of age and will show no evidence of active\n             progressive disease on follow up. For ovarian cancer patients, a woman with a rising\n             CA125 and negative imaging is acceptable."
            }
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02016833", 
            "org_study_id": "PX_DCtagTM_LeadIn_001"
        }, 
        "intervention": {
            "arm_group_label": "Cancer patients", 
            "description": "Sampling of 80mL of whole blood", 
            "intervention_name": "Blood Sampling", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ovarian Cancer", 
            "Cervical Cancer", 
            "Leukemia", 
            "Immunity", 
            "WT-1", 
            "Survivin", 
            "HPV"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Melbourne", 
                    "country": "Australia", 
                    "state": "Victoria", 
                    "zip": "3002"
                }, 
                "name": "Peter MacCallum Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_groups": "1", 
        "official_title": "Phase 0 Study for the Development of Immunological Assays for the Evaluation of WT-1, Survivin and HPV16 E7 Tumor Antigens Specific Immune Responses in Cancer Patients", 
        "overall_official": {
            "affiliation": "Peter MacCallum Cancer Centre, Australia", 
            "last_name": "Linda Mileshkin, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Australia: Human Research Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Direct and cultured IFNg ELISpot as well as direct tetramer staining assays will be set up and qualified for the detection WT-1, survivin and HPV16 E7 specific immune responses in cancer patients", 
            "measure": "Development and validation of ELISpot and tetramer assays for the detection of tumor-antigen specific T cell immune responses in cancer patients", 
            "safety_issue": "No", 
            "time_frame": "Baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02016833"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Direct and Cultured IFNg ELISpot assays as well as tetramer staining assays will be used for the characterization of tumor specific immune responses in cancer patients", 
            "measure": "Characterisation of WT1, Survivin and HPV16 E7 specific immune responses in cancer patients", 
            "safety_issue": "No", 
            "time_frame": "Baseline"
        }, 
        "source": "PX Biosolutions", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PX Biosolutions", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}